[go: up one dir, main page]

WO2003008530A3 - A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method - Google Patents

A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method Download PDF

Info

Publication number
WO2003008530A3
WO2003008530A3 PCT/EP2002/007910 EP0207910W WO03008530A3 WO 2003008530 A3 WO2003008530 A3 WO 2003008530A3 EP 0207910 W EP0207910 W EP 0207910W WO 03008530 A3 WO03008530 A3 WO 03008530A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
microphysiometer
determining
therapeutic effectiveness
statistical model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/007910
Other languages
French (fr)
Other versions
WO2003008530A2 (en
Inventor
Mirko Luedde
Frank Kischkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellcontrol Biomedical Labs AG
Original Assignee
Cellcontrol Biomedical Labs AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellcontrol Biomedical Labs AG filed Critical Cellcontrol Biomedical Labs AG
Priority to AU2002328905A priority Critical patent/AU2002328905A1/en
Publication of WO2003008530A2 publication Critical patent/WO2003008530A2/en
Publication of WO2003008530A3 publication Critical patent/WO2003008530A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

This invention is related to a method for determining the therapeutic effectiveness of a substance using a microphysiometer. It has been found that more accurate results can be achieved by incorporating a statistical model for tumour cells survival under treatment from a chemotherapeutic substance. The statistical model is used in combination with cell metabolic activity measurements obtained using a microphysiometer in order to provide a more accurate and robust method for determining the therapeutic effectiveness of a substance on tumourous cells. The invention also relates to use of the method for improving an objective quantitative measure of chemosensitivity, preferably of tumour cells.
PCT/EP2002/007910 2001-07-16 2002-07-16 A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method Ceased WO2003008530A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002328905A AU2002328905A1 (en) 2001-07-16 2002-07-16 A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134446 2001-07-16
DE10134446.5 2001-07-16

Publications (2)

Publication Number Publication Date
WO2003008530A2 WO2003008530A2 (en) 2003-01-30
WO2003008530A3 true WO2003008530A3 (en) 2003-08-28

Family

ID=7691906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007910 Ceased WO2003008530A2 (en) 2001-07-16 2002-07-16 A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method

Country Status (2)

Country Link
AU (1) AU2002328905A1 (en)
WO (1) WO2003008530A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130330761A1 (en) * 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
AU2018239989A1 (en) 2017-03-20 2019-08-08 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5860917A (en) * 1997-01-15 1999-01-19 Chiron Corporation Method and apparatus for predicting therapeutic outcomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5860917A (en) * 1997-01-15 1999-01-19 Chiron Corporation Method and apparatus for predicting therapeutic outcomes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAFNER FRANK: "Cytosensor(R) Microphysiometer: Technology and recent applications", BIOSENSORS & BIOELECTRONICS, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 15, no. 3-4, June 2000 (2000-06-01), pages 149 - 158, XP002183725, ISSN: 0956-5663 *
J.W.HARBELL ET AL: "Assessment of the cytosensor microphysiometer assay in the COLIPA in vitro eye irritation validation study", TOXICOLOGY IN VITRO, vol. 13, 1999, pages 313 - 323, XP002228156 *
MCCONNELL H M ET AL: "THE CYTOSENSOR MICROPHYSIOMETER: BIOLOGICAL APPLICATIONS OF SILICONTECHNOLOGY", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 257, no. 5078, 25 September 1992 (1992-09-25), pages 1906 - 1912, XP000560386, ISSN: 0036-8075 *
R. METZGER ET AL: "Towards in vitro prediction of an in vivo cytostatic response of human tumor cells with a fast chemosensitivity assay", TOXICOLOGY, vol. 166, 2001 - 14 September 2001 (2001-09-14), pages 97 - 108, XP002228157 *
W. YICONG ET AL: "A novel microphysiometer based on MLAPS for drug screening", BIOSENSORS & BIOELECTRONICS, vol. 16, 2001 - 1 June 2001 (2001-06-01), pages 277 - 286, XP002228155 *

Also Published As

Publication number Publication date
AU2002328905A1 (en) 2003-03-03
WO2003008530A2 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
Smith et al. Exercise-induced oxidative stress: the effects of β-alanine supplementation in women
Buchheit et al. Monitoring locomotor load in soccer: is metabolic power, powerful?
Jegerlehner et al. The O (ααs) correction to the pole mass of the t-quark within the standard model
WO2007070621A3 (en) Prognosis indicators for solid human tumors
TW200730129A (en) Method and apparatus for point of care osmolarity testing
AU2001250412A1 (en) Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
TWI263677B (en) Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products
ATE133049T1 (en) VERIFICATION AND MONITORING TOOL
AU2003285866A1 (en) Methods for assessing efficacy of chemotherapeutic agents
WO2005099716A3 (en) Method for analyzing the biological age of a subject
Lai et al. Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
WO2003008530A3 (en) A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method
ATE439596T1 (en) OXALIPLATIN ANTRESISTANCE PROCESS
Totti et al. Quality of life and energy expenditure in transplant recipient football players
Ivuškāns et al. Role of physical activity in bone health in peripubertal boys
WO2002087612A3 (en) Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases
Kusmierczyk et al. Pre-exercise cryotherapy reduces myoglobin and creatine kinase levels after eccentric muscle stress in young women
TW200613032A (en) Uses for augmenting bone
FR2883184B1 (en) SPIRULINA COMPOSITION RICH IN ACTIVE INGREDIENTS, METHOD OF OBTAINING AND USE
TW200610519A (en) Method for measuring energy consumption and device of the same
RU2004103706A (en) METHOD FOR ESTIMATING TREATMENT EFFICIENCY AND FORECASTING RISK OF RECURRENCE IN DURING DEPRESSIVE DISORDERS
EP1812586A4 (en) Method for testing a compound for a therapeutic effect and a diagnostic method
Abelson et al. Effect of sorbitol sweetened breath mints on salivary flow and plaque pH in xerostomic subjects
EP1773762A4 (en) Methods and compounds for detection of medical disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP